On Wednesday, Accenture Plc (NYSE:ACN)’s shares inclined 1.66% to $96.52.
Accenture Plc (ACN) is expanding its delivery center in Recife, Brazil, adding 1,000 positions by 2017 to support clients that want innovative application services that will assist them grow and operate their businesses more efficiently.
Accenture is one of the largest IT employers in the region with about 1,000 talented professionals possessing deep digital expertise and degrees from the top universities. Accenture has locations across Brazil in São Paulo, Belo Horizonte, Brasilia, Belo Horizonte, Vitória, Recife, Porto Alegre, Curitiba, Alphaville, Campina Grande and Rio de Janeiro.
Located in Porto Digital, the Accenture Delivery Center in Recife is a hub of digital development and innovation in IT systems and outsourcing services for clients across a range of industries, counting finance, health, telecommunications, consumer goods, natural resources, mining, energy and automotive. The location hosts talent exchanges with other operations centers, reinforcing knowledge exchange and best practices.
Accenture plc provides administration consulting, technology, and business process outsourcing services worldwide. The company’s Communications, Media & Technology segment offers enterprise and industry-customized services in network engineering and integration, field force enablement, and IP network migration; provides online customer and enterprise relationship administration services; and assists customers in developing video-over-IP platforms, and transforming legacy broadcast platforms to digital.
Can Fite Biopharma Ltd (ADR) (NYSEMKT:CANF)’s shares gained 2.61% to $2.36.
Can Fite Biopharma Ltd (ADR) (CANF) declared the U.S. Patent & Trademark Office has issued a Notice of Allowance to the Company for an important manufacturing method patent for its drug candidate CF101.
The patent titled, “Process for the synthesis of IB-MECA,” describes a method for the chemical synthesis of the A3 adenosine receptor agonist, IB-MECA, which is the active pharmaceutical ingredient (API) of the CF101 drug candidate. The patent, once issued, will be planned to expire in 2028.
The patent covers a superior method of manufacturing the API of CF101 by reducing the number of synthesis steps. This in turn results in reduced drug development costs, potentially increasing margins on any future sales of CF101.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. It offers CF101, which has accomplished Phase II/III clinical trials for the treatment of psoriasis; accomplished Phase II clinical trials for the treatment of rheumatoid arthritis; accomplished Phase I clinical study for the treatment of osteoarthritis; and accomplished Phase I study for the treatment of uveitis, in addition to is in Phase II clinical trials for the treatment of glaucoma or related syndromes of ocular hypertension.
At the end of Wednesday’s trade, DS Healthcare Group Inc (NASDAQ:DSKX)‘s shares surged 24.84% to $3.92.
DS Healthcare Group Inc (DSKX). The Integra over-the-counter tablet for thinning hair and improved hair health is now here. The first reveal image can be seen on this link: http://dshairclinic.com/letters/Integra.png
It is the world’s first tablet that contains Astressin-B along with a combination of other novel compounds. This product is the result of findings from DS Healthcare Group’s ongoing research on hair loss and related conditions. Astressin-B is a complex peptide that has shown in landmark research that it can reduce the effects of Corticotropin-releasing hormone (CRH) involved in the stress response. CRH is associated with many other diseases and is also believed to have a direct impact on hair health.
DS Healthcare Group, Inc., doing business as DS Laboratories, develops and markets hair care, skin care, and personal care products in North America and internationally. Its hair care products comprise Revita and Revita LT shampoos, and Revita.Cor conditioner for hair growth stimulation; Dandrene, an antifungal shampoo to treat itchy scalp and dandruff; and Spectral line of products comprising Spectral.DNC spray formula, Spectral.DNC-L lotion, and Spectral DNC-N to re-grow hair through various pathways, in addition to Spectral.RS, a topical treatment for men and women with advanced androgenic alopecia.
American Apparel Inc (NYSEMKT:APP), ended its Wednesday’s trading session with -2.59% loss, and closed at $0.545.
American Apparel (APP) declared another leadership appointment. Brian McHale has been named Senior Vice President and Chief Information Officer.
As Chief Information Officer, McHale will oversee information technology and computer systems at the company. In addition to providing critical support to American Apparel’s onsite hardware and software applications, McHale will also lead the development and expansion of the company’s retail digital capabilities alongside Thoryn Stephens, designated Chief Digital Officer.
McHale comes to American Apparel with over 25 years of experience developing IT governance, Business Intelligence and Big Data solutions for some of the U.S.’s largest companies such as DirecTV and Verizon. He has also transformed these companies to cloud-based infrastructures, driving efficiencies and cost savings. McHale’s experience comprises work for agency clients in a variety of categories, counting turnaround businesses, similar to American Apparel.
American Apparel, Inc. designs, manufactures, distributes, retails, and sells branded fashion basic apparel products, and clothing and accessories for women, men, children, and babies. It offers T-shirts, denim, sweaters, jackets, and accessories. The company sells its products through the wholesale distribution channel, counting supplying T-shirts and other casual wear to distributors and screen printers; direct to customers through its retail stores; and through an online retail e-commerce Website, americanapparel.com.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.